Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions

RSVpreF was well tolerated with no safety concerns and demonstrated immunobridging to efficacy in 18-59-year-olds at high risk of severe RSV disease versus ≥60-year-olds in whom efficacy was previously demonstrated, supporting use of RSVpreF to prevent RSV-associated disease in this population. NCT05842967.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2024-11-07
DOI
https://doi.org/10.1093/cid/ciae550
Citations
16
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
6.19

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions

Maria Maddalena Lino, Michael Quinn Patton, David DeAtkine, Elena Kalinina et al.
16 citations
Clinical Infectious Diseases
Respiratory viral infections research
6.19
article

Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions

Maria Maddalena Lino, Michael Quinn Patton, David DeAtkine, Elena Kalinina, Annaliesa S. Anderson, A.P. Chaudhry, Helen Stacey, David Joseph Diemert, Elliot DeHaan, Terry Klein, Jeffrey B. Rosen, Kena A. Swanson, Douglas Denham, Mark M. Davis, David G. Taylor, Matthew Davis, Matthew W. Doust, Mary M. Bailey, Michael Dever, Iona Munjal, Uzma Sarwar, Alejandra Gurtman, Saumil Mehta, David Mishkin, James Clark, Natalia Castillo Almeida, William B. Smith, Qin Jiang, Elissa Malkin, William James Towner, Haresh Boghara, Hayley Wyper, Wen Li, Michael Carter, Farah Rahman, David Cooper, Joseph Davis, Jonathan Cohen, Monica Mauri, Erick Stanley Petersen Juárez, Joel Neutel, Kevin Cannon, Zaynah Majid-Mahomed, William Howitt, Maria Onoya, William Howland, Felipe Suplicy, Ilja Hulinsky
article en
16 citations

Abstract

RSVpreF was well tolerated with no safety concerns and demonstrated immunobridging to efficacy in 18-59-year-olds at high risk of severe RSV disease versus ≥60-year-olds in whom efficacy was previously demonstrated, supporting use of RSVpreF to prevent RSV-associated disease in this population. NCT05842967.

Clinical Infectious DiseasesVol. 80(4)
Kaiser Permanente (US), Pfizer (United States) (US), Wilmington University (US), QPS (United States) (US)
Pfizer
Good health and well-being
Openalex Percentile: Top 3%
Respiratory viral infections research
6.19
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.